All In Biotech

Drug Trial Radar · NCT05593328

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

A Phase 2, Randomized, Open-label Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS or NRAS Mutation

Last checked: Nov 19, 2026Latest source record: Jan 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

23

Actual

Start

Mar 17, 2023

Primary completion

Dec 9, 2024

Study completion Dec 9, 2024

Sponsor

Lead sponsor
Cardiff OncologyIndustry
Sponsor type
Industry
First posted
Oct 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the efficacy of 2 different doses of onvansertib in combination with a chemotherapy regimen of irinotecan, fluorouracil \[5-FU\], and leucovorin (FOLFIRI) and bevacizumab for treatment of confirmed metastatic and/or unresectable colorectal cancer (CRC) in participants with a kirsten rat sarcoma virus gene (KRAS) or neuroblastoma-RAS (NRAS) mutation who have progressed on an oxaliplatin/fluoropyrimidinebased regimen in the first-line setting.

Conditions

  • Colorectal Cancer
  • Metastatic Colorectal Cancer

Interventions

  • OnvansertibDrug

    Oral capsule

  • FOLFIRIDrug

    FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion

  • BevacizumabDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response RateTime frame: Up to approximately 1 year

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona - Phoenix Campus

    Phoenix, Arizona

  • Central Arkansas Radiation Therapy Institute - Cancer Center

    Little Rock, Arkansas

  • Pacific Cancer Medical Center

    Anaheim, California

  • Comprehensive Blood and Cancer Center - Bakersfield

    Bakersfield, California

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California

  • Norris Comprehensive Cancer Center

    Los Angeles, California

  • UCI Health - Chao Family Comprehensive Cancer Center

    Orange, California

  • UCLA Health - Santa Monica Parkside Cancer Care

    Santa Monica, California

  • Torrance Memorial Physician Network - Cancer Care and Infusion Center

    Torrance, California

  • PIH Health

    Whittier, California

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida

  • Memorial Hospital West

    Pembroke Pines, Florida

  • Cancer & Hematology Centers of Western Michigan - Lemmen-Holton Cancer Pavilion

    Grand Rapids, Michigan

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • Washington University School of Medicine Center for Advanced Medicine

    St Louis, Missouri

  • Nebraska Cancer Specialists - Midwest Cancer Center - Legacy

    Omaha, Nebraska

  • Englewood Health

    Englewood, New Jersey

  • San Juan Oncology Associates

    Farmington, New Mexico

  • Manhattan Hematology Oncology Associates

    New York, New York

  • Gabrail Cancer and Research Center

    Canton, Ohio

  • Trihealth Kenwood

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • West Cancer Center - East Campus

    Germantown, Tennessee

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • University of Virginia School of Medicine

    Charlottesville, Virginia

  • Inova Schar Cancer Institute

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.